Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Valentis Posts Fallen Revenue, Widened Loss in Q3

NEW YORK, May 13 - Valentis on Friday reported that falling third-quarter revenue caused a widened net loss.

 

Total revenue for the period ended March 31 fell to $833,000 from $1 million in the year-ago quarter.

 

R&D followed suit, decreasing to $5.6 million in the third quarter 2002 from $6.9 million one year ago.

 

Net loss widened to $11 million, or $.30 per basic and diluted share compared with $10.2 million, or $.34 per basic and diluted share, year over year, the company reported

 

Valentis said it had roughly $25.2 million in cash, cash equivalents, and short-term investments as of March 31.

 

Click here for more information.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.